Onconic Therapeutics (476060) Financial Statements

Income Statement

YearRevenueOp ProfitNet IncomeSource
202512.6 billion KRW15.8 billion KRW[source]
2024-4.8 billion KRW-8.1 billion KRW[source]
20232.2 billion KRW1.7 billion KRW
2022-14.8 billion KRW-14.4 billion KRW

Balance Sheet

YearTotal AssetsTotal LiabilitiesTotal EquitySource
202575.7 billion KRW3.7 billion KRW72.0 billion KRW[source]
202460.9 billion KRW4.9 billion KRW56.0 billion KRW[source]
2023
2022

This company has no revenue account in the DART financial statements. Industry-specific accounts such as insurance or interest income are not converted to revenue.

Years without a source link are outside the DART financial API collection period.